Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
IPO Date: November 9, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $2.3B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.02 | 2.82%
Avg Daily Range (30 D): $0.44 | 2.50%
Avg Daily Range (90 D): $0.51 | 2.45%
Institutional Daily Volume
Avg Daily Volume: 1.07M
Avg Daily Volume (30 D): 1.93M
Avg Daily Volume (90 D): 1.73M
Trade Size
Avg Trade Size (Sh.): 78
Avg Trade Size (Sh.) (30 D): 74
Avg Trade Size (Sh.) (90 D): 74
Institutional Trades
Total Inst.Trades: 7,429
Avg Inst. Trade: $3.32M
Avg Inst. Trade (30 D): $4.67M
Avg Inst. Trade (90 D): $4.96M
Avg Inst. Trade Volume: .08M
Avg Inst. Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $7.22M
Avg Closing Trade (30 D): $8.26M
Avg Closing Trade (90 D): $9.76M
Avg Closing Volume: 176.56K
   
News
Jun 16, 2025 @ 5:00 PM
Comprehensive Age-related Macular Degeneration Mar...
Source: Delveinsight
May 7, 2025 @ 10:09 PM
Why Apellis Pharmaceuticals Wilted on Wednesday
Source: Eric Volkman
Feb 24, 2025 @ 12:00 PM
Apellis Pharmaceuticals to Present at the TD Cowen...
Source: N/A
Feb 20, 2025 @ 7:00 AM
Apellis and Sobi Announce EMA Validation of Indica...
Source: N/A
Feb 14, 2025 @ 12:00 PM
Apellis Pharmaceuticals to Host Conference Call on...
Source: N/A
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-1.79 $-.74 $-.29
Diluted EPS $-1.79 $-.74 $-.29
Revenue $ 775.84M $ 166.8M $ 212.53M
Gross Profit $ $ $
Net Income / Loss $ -223.68M $ -92.23M $ -36.35M
Operating Income / Loss $ -186.22M $ -83.33M $ -26.16M
Cost of Revenue $ $ $
Net Cash Flow $ 32.8M $ -52.79M $ 14.38M
PE Ratio    
Splits
Mar 19, 2004:   1:200